Singapore markets close in 1 hour 20 minutes
  • Straits Times Index

    3,358.72
    -18.93 (-0.56%)
     
  • Nikkei

    27,402.05
    +55.17 (+0.20%)
     
  • Hang Seng

    22,036.40
    -35.78 (-0.16%)
     
  • FTSE 100

    7,761.11
    -10.59 (-0.14%)
     
  • BTC-USD

    23,795.26
    +689.80 (+2.99%)
     
  • CMC Crypto 200

    542.82
    +300.14 (+123.68%)
     
  • S&P 500

    4,119.21
    +42.61 (+1.05%)
     
  • Dow

    34,092.96
    +6.92 (+0.02%)
     
  • Nasdaq

    11,816.32
    +231.77 (+2.00%)
     
  • Gold

    1,972.50
    +29.70 (+1.53%)
     
  • Crude Oil

    76.91
    +0.50 (+0.65%)
     
  • 10-Yr Bond

    3.3970
    0.0000 (0.00%)
     
  • FTSE Bursa Malaysia

    1,489.09
    +3.59 (+0.24%)
     
  • Jakarta Composite Index

    6,882.48
    +20.22 (+0.29%)
     
  • PSE Index

    6,986.19
    -49.57 (-0.70%)
     

Organon To Present at the Piper Sandler 34th Annual Healthcare Conference

JERSEY CITY, N.J., November 15, 2022--(BUSINESS WIRE)--Organon (NYSE: OGN), announced today that Kevin Ali, Chief Executive Officer, and Matthew Walsh, Chief Financial Officer, are scheduled to participate in a fireside chat at the Piper Sandler 34th Annual Healthcare Conference on Tuesday, November 29th, 2022 at 9:00 a.m. EST.

Investors, analysts, members of the media and the general public are invited to listen to a live audio webcast of the presentation at https://www.organon.com/investor-relations/events-and-presentations/.

About Organon

Organon is a global healthcare company formed to focus on improving the health of women throughout their lives. Organon has a portfolio of more than 60 medicines and products across a range of therapeutic areas. Led by the women’s health portfolio coupled with an expanding biosimilars business and stable franchise of established medicines, Organon’s products produce strong cash flows that will support investments in innovation and future growth opportunities in women’s health. In addition, Organon is pursuing opportunities to collaborate with biopharmaceutical innovators looking to commercialize their products by leveraging its scale and presence in fast growing international markets.

Organon has a global footprint with significant scale and geographic reach, world-class commercial capabilities, and approximately 10,000 employees with headquarters located in Jersey City, New Jersey.

For more information, visit http://www.organon.com and connect with us on LinkedIn and Instagram.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221115005268/en/

Contacts

Media Contacts:

Karissa Peer
(614) 314-8094

Kate Vossen
(732) 675-8448

Investor Contacts:

Jennifer Halchak
(201) 275-2711